Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...
Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...
Our office serves first-generation students, students from income-eligible backgrounds and students with a documented disability as they work toward earning their college degree. If you are one such ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback